ELDN vs. PSTX, OCS, NUVB, AVXL, ABCL, CVAC, AVBP, COGT, PAHC, and RLAY
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs.
Poseida Therapeutics (NASDAQ:PSTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.
Poseida Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 0.00%. Eledon Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 293.60%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Poseida Therapeutics.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Poseida Therapeutics' net margin of -40.28%. Poseida Therapeutics' return on equity of -72.26% beat Eledon Pharmaceuticals' return on equity.
Eledon Pharmaceuticals has lower revenue, but higher earnings than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Poseida Therapeutics. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Poseida Therapeutics. Poseida Therapeutics' average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.15 indicating that Poseida Therapeutics is being referred to more favorably in the media.
Poseida Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
46.9% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 2.9% of Poseida Therapeutics shares are held by company insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Poseida Therapeutics received 13 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 63.49% of users gave Poseida Therapeutics an outperform vote.
Summary
Eledon Pharmaceuticals beats Poseida Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ELDN Stock Alerts